Skip to main content
Scandion Oncology A/S logo

Scandion Oncology A/S — Investor Relations & Filings

Ticker · SCOL ISIN · DK0061031895 LEI · 549300MPWDMQ5LZEGD09 ST Professional, scientific and technical activities
Open in API
Filings indexed 4 across all filing types
Latest filing 2024-05-31 Capital/Financing Update
Country DK Denmark
Listing ST SCOL

About Scandion Oncology A/S

https://scandiononcology.com/

Scandion Oncology A/S is a biotechnology company currently under liquidation. Prior to this, it operated as a clinical-stage firm focused on developing therapies to overcome cancer drug resistance. The company's primary objective was to develop first-in-class, oral add-on drugs designed to reverse resistance and enhance the efficacy of existing cancer treatments. Its lead compound was SCO-101, which was investigated in clinical trials for its potential to restore the effectiveness of chemotherapy in patients with various types of cancer.

Recent filings

Filing Released Lang Actions
Approval of prospectus for Scandion Oncology A/S; Derivatives
Capital/Financing Update Classification · 1% confidence The document is a 'EU-tillväxtprospekt' (EU Growth Prospectus) for Scandion Oncology A/S, dated May 31, 2024. It details a rights issue (företrädesemission) of units consisting of shares and warrants. While it contains financial data, it is fundamentally a prospectus document used for capital raising and regulatory compliance regarding the issuance of new securities. In the provided taxonomy, documents related to capital raising, financing activities, and share issues are classified under 'CAP' (Capital/Financing Update).
2024-05-31 Swedish
Approval of prospectus for Scandion Oncology A/S; Derivatives
Capital/Financing Update Classification · 1% confidence The document is a formal 'EU Growth Prospectus' for Scandion Oncology A/S, detailing a rights issue of units (shares and warrants). It includes regulatory approval from the Danish Financial Supervisory Authority, terms of the offering, risk factors, and financial information. While it contains financial data, it is a capital-raising document rather than an annual or interim report. Under the provided categories, documents related to fundraising and capital structure changes are classified as 'CAP'.
2024-05-31 English
Approval of prospectus for Scandion Oncology A/S; Shares
Capital/Financing Update Classification · 1% confidence The document is a formal 'EU Growth Prospectus' for Scandion Oncology A/S, detailing a rights issue of shares. It includes sections on the offering, risk factors, business overview, and financial information incorporated by reference. While it contains financial data, it is not an annual or interim report itself, but rather a regulatory document required for a capital raise. Under the provided categories, this fits best as a 'Capital/Financing Update' (CAP) as it relates to the issuance of new shares and the terms of the rights issue.
2022-06-15 English
Godkendelse af prospekt for Scandion Oncology A/S , Aktier, 17.06.2019
Capital/Financing Update Classification · 1% confidence The document is a formal 'Prospectus' for Scandion Oncology A/S, detailing an 'Invitation to Subscribe for Units' (a rights issue or capital raise). It contains sections on the offering, risk factors, financial overview, and terms of the capital increase. In financial document classification, a prospectus for a share or unit offering is categorized under Capital/Financing Update (CAP).
2019-06-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.